Blood-based Genomic Screening (BGS) Panel
8 Common Cancers
Key Facts
About BioNexus Gene Lab
BioNexus Gene Lab leverages a pioneering blood-based genomic screening (BGS) platform, founded on research by the late Professor Emeritus Dato Dr. Liew Choong-Chin, to detect disease predisposition before symptom onset. The company operates as a US-incorporated public entity (BGLC) with a wholly-owned Malaysian subsidiary, MRNA SCIENTIFIC SDN BHD, serving as its global testing center. Its core offering is a less-invasive blood test that uses FDA-approved reagents and proprietary software to generate predictive risk scores, aiming to shift healthcare towards early intervention and prevention.
View full company profileAbout BioNexus Gene Lab
BioNexus Gene Lab leverages a pioneering blood-based genomic screening (BGS) platform, founded on research by the late Professor Emeritus Dato Dr. Liew Choong-Chin, to detect disease predisposition before symptom onset. The company operates as a US-incorporated public entity (BGLC) with a wholly-owned Malaysian subsidiary, MRNA SCIENTIFIC SDN BHD, serving as its global testing center. Its core offering is a less-invasive blood test that uses FDA-approved reagents and proprietary software to generate predictive risk scores, aiming to shift healthcare towards early intervention and prevention.
View full company profileAbout BioNexus Gene Lab
BioNexus Gene Lab leverages a pioneering blood-based genomic screening (BGS) platform, founded on research by the late Professor Emeritus Dato Dr. Liew Choong-Chin, to detect disease predisposition before symptom onset. The company operates as a US-incorporated public entity (BGLC) with a wholly-owned Malaysian subsidiary, MRNA SCIENTIFIC SDN BHD, serving as its global testing center. Its core offering is a less-invasive blood test that uses FDA-approved reagents and proprietary software to generate predictive risk scores, aiming to shift healthcare towards early intervention and prevention.
View full company profile